Contrast ultrasound in imaging tumor angiogenesis

Grzegorz Korpanty, Rolf A. Brekken

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

New strategies to detect tumor angiogenesis and monitor response of tumor vasculature to therapy are needed. There are a plethora of anti-angiogenic strategies being evaluated pre-clinically and in the clinical setting; however, a -significant unmet challenge is following the response of tumors to anti-angiogenic therapy. Herein we review current modalities being investigated for this purpose and highlight the utility of contrast ultrasound imaging using targeted microbubbles (MB). MB are small (1-10 μm) gas-filled intravascular tracers. MB can be targeted via antibodies, peptides or other moieties to virtually any endothelial cell surface marker and thus selectively mark specific vascular beds (e.g., tumor blood vessels). Furthermore targeted MB can be used to non-invasively evaluate the expression level of particular molecular antigens (e.g., CD105, VEGFR2) and monitor the effect of therapy on target expression. We conclude that targeted MB represent a novel and attractive tool for non-invasive, vascular-targeted molecular imaging of tumor angiogenesis and for monitoring vascular effects specific to anti-tumor therapy in vivo.

Original languageEnglish (US)
Title of host publicationVascular Disruptive Agents for the Treatment of Cancer
PublisherSpringer New York
Pages165-179
Number of pages15
ISBN (Print)9781441966087
DOIs
StatePublished - 2010

Fingerprint

Microbubbles
Tumors
Ultrasonography
Ultrasonics
Imaging techniques
Blood Vessels
Neoplasms
Vascular Tissue Neoplasms
Molecular Imaging
Molecular imaging
Therapeutics
Endothelial cells
Blood vessels
Endothelial Cells
Gases
Peptides
Antibodies
Antigens
Monitoring

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Korpanty, G., & Brekken, R. A. (2010). Contrast ultrasound in imaging tumor angiogenesis. In Vascular Disruptive Agents for the Treatment of Cancer (pp. 165-179). Springer New York. https://doi.org/10.1007/978-1-4419-6609-4_8

Contrast ultrasound in imaging tumor angiogenesis. / Korpanty, Grzegorz; Brekken, Rolf A.

Vascular Disruptive Agents for the Treatment of Cancer. Springer New York, 2010. p. 165-179.

Research output: Chapter in Book/Report/Conference proceedingChapter

Korpanty, G & Brekken, RA 2010, Contrast ultrasound in imaging tumor angiogenesis. in Vascular Disruptive Agents for the Treatment of Cancer. Springer New York, pp. 165-179. https://doi.org/10.1007/978-1-4419-6609-4_8
Korpanty G, Brekken RA. Contrast ultrasound in imaging tumor angiogenesis. In Vascular Disruptive Agents for the Treatment of Cancer. Springer New York. 2010. p. 165-179 https://doi.org/10.1007/978-1-4419-6609-4_8
Korpanty, Grzegorz ; Brekken, Rolf A. / Contrast ultrasound in imaging tumor angiogenesis. Vascular Disruptive Agents for the Treatment of Cancer. Springer New York, 2010. pp. 165-179
@inbook{e469deeea3324577a673b9b7e323bcdb,
title = "Contrast ultrasound in imaging tumor angiogenesis",
abstract = "New strategies to detect tumor angiogenesis and monitor response of tumor vasculature to therapy are needed. There are a plethora of anti-angiogenic strategies being evaluated pre-clinically and in the clinical setting; however, a -significant unmet challenge is following the response of tumors to anti-angiogenic therapy. Herein we review current modalities being investigated for this purpose and highlight the utility of contrast ultrasound imaging using targeted microbubbles (MB). MB are small (1-10 μm) gas-filled intravascular tracers. MB can be targeted via antibodies, peptides or other moieties to virtually any endothelial cell surface marker and thus selectively mark specific vascular beds (e.g., tumor blood vessels). Furthermore targeted MB can be used to non-invasively evaluate the expression level of particular molecular antigens (e.g., CD105, VEGFR2) and monitor the effect of therapy on target expression. We conclude that targeted MB represent a novel and attractive tool for non-invasive, vascular-targeted molecular imaging of tumor angiogenesis and for monitoring vascular effects specific to anti-tumor therapy in vivo.",
author = "Grzegorz Korpanty and Brekken, {Rolf A.}",
year = "2010",
doi = "10.1007/978-1-4419-6609-4_8",
language = "English (US)",
isbn = "9781441966087",
pages = "165--179",
booktitle = "Vascular Disruptive Agents for the Treatment of Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Contrast ultrasound in imaging tumor angiogenesis

AU - Korpanty, Grzegorz

AU - Brekken, Rolf A.

PY - 2010

Y1 - 2010

N2 - New strategies to detect tumor angiogenesis and monitor response of tumor vasculature to therapy are needed. There are a plethora of anti-angiogenic strategies being evaluated pre-clinically and in the clinical setting; however, a -significant unmet challenge is following the response of tumors to anti-angiogenic therapy. Herein we review current modalities being investigated for this purpose and highlight the utility of contrast ultrasound imaging using targeted microbubbles (MB). MB are small (1-10 μm) gas-filled intravascular tracers. MB can be targeted via antibodies, peptides or other moieties to virtually any endothelial cell surface marker and thus selectively mark specific vascular beds (e.g., tumor blood vessels). Furthermore targeted MB can be used to non-invasively evaluate the expression level of particular molecular antigens (e.g., CD105, VEGFR2) and monitor the effect of therapy on target expression. We conclude that targeted MB represent a novel and attractive tool for non-invasive, vascular-targeted molecular imaging of tumor angiogenesis and for monitoring vascular effects specific to anti-tumor therapy in vivo.

AB - New strategies to detect tumor angiogenesis and monitor response of tumor vasculature to therapy are needed. There are a plethora of anti-angiogenic strategies being evaluated pre-clinically and in the clinical setting; however, a -significant unmet challenge is following the response of tumors to anti-angiogenic therapy. Herein we review current modalities being investigated for this purpose and highlight the utility of contrast ultrasound imaging using targeted microbubbles (MB). MB are small (1-10 μm) gas-filled intravascular tracers. MB can be targeted via antibodies, peptides or other moieties to virtually any endothelial cell surface marker and thus selectively mark specific vascular beds (e.g., tumor blood vessels). Furthermore targeted MB can be used to non-invasively evaluate the expression level of particular molecular antigens (e.g., CD105, VEGFR2) and monitor the effect of therapy on target expression. We conclude that targeted MB represent a novel and attractive tool for non-invasive, vascular-targeted molecular imaging of tumor angiogenesis and for monitoring vascular effects specific to anti-tumor therapy in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84900041187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900041187&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-6609-4_8

DO - 10.1007/978-1-4419-6609-4_8

M3 - Chapter

SN - 9781441966087

SP - 165

EP - 179

BT - Vascular Disruptive Agents for the Treatment of Cancer

PB - Springer New York

ER -